Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.San Francisco medical technology firm Medivation has enrolled a total of 183 patients in its ongoing phase II clinical trial of Dimebon to treat Alzheimer's disease, exceeding its projected target of 166 patients.
Subscribe to our email newsletter
The company also announced it has closed enrollment of further patients into the study and, based on the study’s 26 week dosing period, reaffirmed its prior forecast that the results of the investigation are scheduled to be announced in the third quarter of 2006.
Dr David Hung, president and CEO of Medivation, said; “Our ability to enroll more than the targeted number of patients will increase the statistical power of this study. In addition, the achievement of this important milestone means we remain on track to deliver results from this trial as scheduled in the third quarter of this year.”
Dimebon is currently in a randomized, double-blind, placebo-controlled phase II study in Alzheimer’s disease patients in Russia. The results of this investigation are expected to be available in Q3 2006. Medivation also expects to initiate a US phase I/II study of Dimebon in Huntington’s disease patients in Q2 2006.